Chengdu Institute of Biological Products, part of China National Biotec, is the first to win international approval from the World Health Organisation for one of its products; the live attenuated vaccine SA 14-14-2 against Japanese encephalitis (JE) including paediatric use has received pre-approval paving the way for future low cost generic competition and wide-spread distribution globally.
